oregovomab

oregovomab information and resources from the National Cancer Institute

oregovomab

A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125.

ViRexx Announces Enrollment Completion of Ovarex'R' MAb Phase III ... Dec 14, 2005
CCNMatthews (Communiqués de presse), OvaRex ® MAb-B43.13 (oregovomab), is a monoclonal antibody developed by ViRexx that has a high degree of specificity to a tumor associated antigen (CA125 ...

Unither Pharmaceuticals Completes Enrollment in First of Two Phase ... Dec 12, 2005
PR Newswire (press release), OvaRex, MAb-B43.13 (oregovomab), is an investigational immunotherapeutic monoclonal antibody being developed for the treatment of stage III/IV advanced ovarian ...

oregovomab -->